Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
- Crossover allows participants to continue in trials and remain blinded
- Ensures that all trial participants receive active vaccine
South Africaand UKcrossover arms initiated; US/Mexico PREVENT-19 crossover planned
"The crossover arms ensure that all participants have access to an active vaccine candidate while allowing
The company is also planning a crossover in the PREVENT-19 study, for which the company expects to read out initial clinical data during the second quarter. In addition, the company is planning to expand the trial to include pediatric and adolescent arms, which are also expected to begin in the second quarter.
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials, a trial in the
NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
Novavax Forward Looking Statements
Statements herein relating to the future of
1 Clinical trial protocols may be found in the Resources section of the